Dashboard
Manage Tickers

VSTM Verastem, Inc.

Nasdaq verastem.com


$ 7.50 $ -0.40 (-4.7 %)    

Thursday, 13-Nov-2025 18:31:22 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 608.59 $ -9.26 (-1.5 %)
DIA $ 475.50 $ -6.59 (-1.37 %)
SPY $ 672.57 $ -8.41 (-1.24 %)
TLT $ 89.38 $ -0.42 (-0.46 %)
GLD $ 384.40 $ -4.31 (-1.11 %)
$ 8.11
$ 8.47
$ 7.30 x 95
$ 7.50 x 700
-- - --
$ 3.46 - $ 11.25
1,068,326
na
541.55M
$ 1.29
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-04-2025 09-30-2025 10-Q
2 08-07-2025 06-30-2025 10-Q
3 05-13-2025 03-31-2025 10-Q
4 03-20-2025 12-31-2024 10-K
5 11-06-2024 09-30-2024 10-Q
6 08-08-2024 06-30-2024 10-Q
7 05-09-2024 03-31-2024 10-Q
8 03-14-2024 12-31-2023 10-K
9 11-08-2023 09-30-2023 10-Q
10 08-08-2023 06-30-2023 10-Q
11 05-09-2023 03-31-2023 10-Q
12 03-14-2023 12-31-2022 10-K
13 11-03-2022 09-30-2022 10-Q
14 08-08-2022 06-30-2022 10-Q
15 05-09-2022 03-31-2022 10-Q
16 03-28-2022 12-31-2021 10-K
17 11-04-2021 09-30-2021 10-Q
18 08-02-2021 06-30-2021 10-Q
19 05-11-2021 03-31-2021 10-Q
20 03-18-2021 12-31-2020 10-K
21 11-09-2020 09-30-2020 10-Q
22 08-10-2020 06-30-2020 10-Q
23 05-07-2020 03-31-2020 10-Q
24 03-11-2020 12-31-2019 10-K
25 10-30-2019 09-30-2019 10-Q
26 08-01-2019 06-30-2019 10-Q
27 05-09-2019 03-31-2019 10-Q
28 03-12-2019 12-31-2018 10-K
29 11-07-2018 09-30-2018 10-Q
30 08-08-2018 06-30-2018 10-Q
31 05-03-2018 03-31-2018 10-Q
32 03-13-2018 12-31-2017 10-K
33 11-07-2017 09-30-2017 10-Q
34 08-08-2017 06-30-2017 10-Q
35 05-10-2017 03-31-2017 10-Q
36 03-23-2017 12-31-2016 10-K
37 11-07-2016 09-30-2016 10-Q
38 08-08-2016 06-30-2016 10-Q
39 05-09-2016 03-31-2016 10-Q
40 03-03-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

verastem-oncology-announces-common-stock-offering-terms-not-disclosed
Verastem Oncology Announces Common Stock O...
11/13/2025 21:10:38

Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pa...

verastem-q3-adj-eps-054-beats-064-estimate-sales-11242m-beat-5659m-estimate
Verastem Q3 Adj. EPS $(0.54) Beats $(0.64)...
11/04/2025 12:31:26

Verastem (NASDAQ:VSTM) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of $(0.64) by 1...

earnings-scheduled-for-november-4-2025
Earnings Scheduled For November 4, 2025
11/04/2025 11:12:08

verastem-reveals-preliminary-data-from-the-first-two-dose-levels-in-its-ongoing-phase-12a-clinical-trial-evaluating-vs-7375-first-two-monotherapy-dose-levels--cleared-with-no-dose-limiting-toxicities-reported-enrollment-initiated-for-vs-7375-in-combination-with-cetuximab-in-patients-with-advanced-kras-g12d-mutant-solid-tumors-including-colorectal-cancer
Verastem Reveals Preliminary Data From The...
10/23/2025 20:08:49

First two monotherapy dose levels (400 mg QD and 600 mg QD) cleared, with no dose-limiting toxicities reportedPromising anti-tu...

reported-sunday-verastem-and-genfleet-report-41-overall-response-rate-915-tumor-reduction-and-967-disease-control-rate-with-gfh375-vs-7375-monotherapy-in-advanced-kras-g12d-mutant-pancreatic-cancer-at-600-mg-dose
Reported Sunday, Verastem And GenFleet Rep...
10/20/2025 07:42:48

GFH375 resulted in a 41% ORR for patients with heavily pre-treated pancreatic ductal adenocarcinoma (68% had received 2 or more...

cantor-fitzgerald-assumes-verastem-at-overweight
Cantor Fitzgerald Assumes Verastem at Over...
10/16/2025 13:17:32

Cantor Fitzgerald analyst Eric Schmidt assumes Verastem (NASDAQ:VSTM) with a Overweight rating.

btig-reiterates-buy-on-verastem-maintains-20-price-target
BTIG Reiterates Buy on Verastem, Maintains...
09/09/2025 11:13:23

BTIG analyst Justin Zelin reiterates Verastem (NASDAQ:VSTM) with a Buy and maintains $20 price target.

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
08/13/2025 21:06:15

verastem-oncology-announces-688-response-rate-for-kras-g12d-inhibitor-gfh375-in-nsclc-data-to-be-presented-at-wclc-2025
Verastem Oncology Announces 68.8% Response...
08/13/2025 20:32:32

GFH375 demonstrated an overall response rate (ORR) of 68.8% in non-small cell lung cancer (NSCLC) at the recommended Phase 2 do...

rbc-capital-maintains-outperform-on-verastem-raises-price-target-to-13
RBC Capital Maintains Outperform on Verast...
08/08/2025 18:42:34

RBC Capital analyst Leonid Timashev maintains Verastem (NASDAQ:VSTM) with a Outperform and raises the price target from $12 ...

verastem-q2-adj-eps-063-beats-074-estimate-sales-2137m-miss-5054m-estimate
Verastem Q2 Adj. EPS $(0.63) Beats $(0.74)...
08/07/2025 20:13:27

Verastem (NASDAQ:VSTM) reported quarterly losses of $(0.63) per share which beat the analyst consensus estimate of $(0.74) by 1...

Core News & Articles
Earnings Scheduled For August 7, 2025
08/07/2025 08:33:15

verastem-gets-fda-boost-for-new-oral-treatment-targeting-aggressive-pancreatic-tumors
Verastem Gets FDA Boost for New Oral Treat...
07/24/2025 11:34:37

Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pa...

verastems-ovarian-cancer-trial-results-published-in-journal-of-clinical-oncology-titled-efficacy-and-safety-of-avutometinib--defactinib-in-recurrent-low-grade-serous-ovarian-cancer-verastems-avutometinib-combo-shows-31-overall-response-rate-in-ovarian-cancer-trial
Verastem's Ovarian Cancer Trial Results Pu...
07/11/2025 20:15:11

Robust objective response rates were observed (31% overall, 44% in KRAS-mutant, and 17% in KRAS wild-type) in patients whose ca...

verastem-oncology-announces-publication-of-updated-results-from-phase-12-frame-study-conducted-by-the-institute-of-cancer-research-london-and-the-royal-marsden-nhs-foundation-trust-in-nature-medicine
Verastem Oncology Announces Publication Of...
06/30/2025 20:05:25

FRAME study demonstrated a 42.3% ORR and 20.1 months median PFS for all patients with low-grade serous ovarian cancer (LGSOC), ...

rbc-capital-maintains-outperform-on-verastem-lowers-price-target-to-12
RBC Capital Maintains Outperform on Verast...
06/25/2025 14:38:58

RBC Capital analyst Leonid Timashev maintains Verastem (NASDAQ:VSTM) with a Outperform and lowers the price target from $16 ...

verastem-oncology-doses-first-patient-with-vs-7375-in-phase-12a-trial
Verastem Oncology Doses First Patient With...
06/24/2025 20:02:55

Core News & Articles
12 Health Care Stocks Moving In Monday's I...
06/02/2025 17:06:00

nasdaq-edges-higher-ism-manufacturing-pmi-falls-in-may
Nasdaq Edges Higher; ISM Manufacturing PMI...
06/02/2025 16:49:43

whats-going-on-with-verastem-oncology-stock-on-monday
What's Going On With Verastem Oncology Sto...
06/02/2025 16:41:21

Verastem's GFH375 trial data at ASCO 2025 shows a 52% response rate in pancreatic cancer and no dose-limiting toxicities ac...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION